Becton Dickinson and Co
bd.comWhat Do They Do?
Sells medical devices and supplies, including drug-delivery systems and medication-management equipment, to hospitals and clinics, pharmaceutical companies, and consumers and retail pharmacies.
10-K for FY2025, filed Nov 25, 2025BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices…View ↗
BD Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of…View ↗
Peripheral intravenous (“IV”) catheters (conventional, safety); advanced peripheral catheters (guidewire assisted peripherally inserted…View ↗
IV medication safety and infusion therapy delivery systems, including infusion pumps, dedicated disposables, and IV fluids; medication…View ↗
Prefillable drug delivery systems - prefillable syringes, safety, shielding and self-injection systems and support services (combination…View ↗
How Do They Make Money?
Customers buy medical supplies, devices, laboratory equipment and diagnostic products; BD generally receives payment within one year or less. Most product sales are counted when shipped or delivered, while certain complex installed equipment is counted after customer acceptance; extended warranties and software maintenance are provided over their contract terms.
10-K for FY2025, filed Nov 25, 2025The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through…View ↗
Timing of Revenue RecognitionView ↗
Payment terms extended to the Company’s customers are based upon commercially reasonable terms for the markets in which the Company's…View ↗
-
10-K for FY2025, filed Nov 25, 2025
FY2025 revenue by reportable segment ↗
$21.8B
-
10-K for FY2025, filed Nov 25, 2025
$21.8B ↗
| Segment | Share | Revenue |
|---|---|---|
|
Medical
|
52%
FY2022: 47%
|
Medical, FY2025
$11.5B Sources
|
|
Life Sciences
|
24%
FY2022: 29%
|
Life Sciences, FY2025
$5.2B Sources
|
|
Interventional
|
24%
FY2022: 24%
|
Interventional, FY2025
$5.2B Sources
|
Who Are Their Customers?
Hospitals, clinics and laboratories; pharmaceutical and biotechnology companies; and physicians and other healthcare providers buy BD products. BD sells through independent distributors and sales representatives and directly to end users; in the United States, wholesalers support disposable-product sales, while most capital equipment is sold directly.
10-K for FY2025, filed Nov 25, 2025The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through…View ↗
BD’s products are marketed and distributed in the United States and internationally through independent distribution channels, as well as…View ↗
Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of…View ↗
Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to…View ↗
Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 8 cents of every revenue dollar as net income in FY2025.
10-K for FY2025, filed Nov 25, 2025
How Are They Changing?
-
Aug 6, 2026
BD raises the midpoint of adjusted EPS guidance
The company expects revenue growth toward the high end of its range.
Sources
8-K, filed Aug 6, 2026
Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23…View ↗
-
Feb 9, 2026
BD completes the Biosciences and Diagnostic Solutions combination with Waters
The transaction brought BD $4 billion in cash.
Sources
8-K, filed Feb 9, 2026
In connection with the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD…View ↗
Growing. Revenue grew 14% in 4 years, from $19.1B in FY2021 to $21.8B in FY2025, about 3% a year.
Surgical instrumentation
The earlier Surgery lineup included surgical and laparoscopic instruments; BD later sold the Surgical Instrumentation platform.
10-K for FY2022, filed Nov 22, 2022 10-K for FY2025, filed Nov 25, 2025Hernia and soft tissue repair, biological grafts, bioresorbable grafts, biosurgery, and other surgical products, BD ChloraPrep™ surgical…View ↗
In August 2023, BD completed the sale of the Interventional segment’s Surgical Instrumentation platform pursuant to a definitive agreement…View ↗
Loading...
